Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
NCT07508605
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Relapsed/Refractory B-cell Lymphoma
Interventions
COMBINATION_PRODUCT:
CAR/TRuC-T
Sponsor
Shenzhen University General Hospital